Evolus Reports Improved Q1 Losses & Cash Flow, Secures New Credit Facility, but Faces Significant New Tariff Risks
Summary
Evolus reported improved Q1 2026 financial results with reduced losses and cash burn, secured a new $30M credit facility, and terminated its ATM program, but highlighted a new, significant risk of potential 100% tariffs on its key product, Jeuveau.
Key Events
-
Improved Q1 Financial Performance
The company reported a net loss of $10.7 million for Q1 2026, an improvement from a $18.9 million net loss in Q1 2025. Net cash used in operating activities decreased to $10.0 million from $15.6 million in the prior year period, and revenue increased by 6.7% to $73.1 million.
-
New Revolving Credit Facility Secured
Evolus entered into a new $30.0 million senior secured asset-based revolving credit facility on March 3, 2026, with an uncommitted accordion feature of up to an additional $10.0 million, enhancing its liquidity.
-
ATM Offering Program Terminated
The $50.0 million At-the-Market (ATM) Sales Agreement, established in March 2023, was terminated on May 1, 2026, with no shares having been sold under the program, removing a potential source of future dilution.
-
Significant New Tariff Risk Identified
The company disclosed a new risk of potential tariffs up to 100% on patented pharmaceuticals imported from South Korea, which could impact its Jeuveau product starting in September 2026, posing a material adverse effect on operations and financial condition.
Analysis
Evolus, Inc. filed its Q1 2026 10-Q, detailing improved financial performance with a reduced net loss and lower cash burn from operations compared to the prior year. The company reported a net loss of $10.7 million, an improvement from $18.9 million in Q1 2025, and operating cash flow improved to a $10.0 million use of cash from $15.6 million in the prior year. Revenue increased by 6.7% to $73.1 million. The company also strengthened its liquidity by securing a new $30.0 million senior secured asset-based revolving credit facility and terminated its $50.0 million At-the-Market (ATM) program without issuing any shares, removing a potential dilution overhang. However, the filing introduces a significant new risk factor: potential tariffs of up to 100% on patented pharmaceuticals imported from South Korea, which could apply to its key product, Jeuveau, starting in September 2026. This tariff risk represents a substantial potential headwind to future profitability and supply chain stability. Investors should monitor the impact of these potential tariffs and the company's ability to mitigate them.
At the time of this filing, EOLS was trading at $5.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $363M. The 52-week trading range was $3.86 to $12.28. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.